Next 10 |
home / stock / cqpty / cqpty news
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants PR Newswire The current market for breast implants is estimated at $2.6 billion a year CollPlant expects the study to conclude by the first half of 2024 CollPlant ...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION PR Newswire - Conference call to be held on Wednesday, November 29, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Nov. 9, 2023 /P...
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler PR Newswire - Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Potential Products - REHOVOT, Israel , Nov. 1, 2023 /PRNe...
CollPlant to Present at the H.C. Wainwright Annual Growth Conference PR Newswire REHOVOT, Israel , Sept. 5, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and produc...
CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million PR Newswire Received in July 2023 , $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal ...
CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal Filler Product Collaboration Agreement PR Newswire REHOVOT, Israel , June 26, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerat...
CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives PR Newswire Study demonstrated progressive stages of tissue regeneration as highlighted by the formation of maturing connective ti...
CollPlant Biotechnologies to Participate in September Investor Conferences PR Newswire REHOVOT, Israel , Sept. 6, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human ...
CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results PR Newswire Co-development of rhCollagen-based dermal and soft tissue fillers with AbbVie is progressing Company's 3D bioprinted regenerative breast implant program remain...
CollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada PR Newswire At the Tissue Engineering and Regenerative Medicine International Society conference, CollPlant will deliver a presentation ' rhCollagen - The Ideal Building Block For 3D ...
News, Short Squeeze, Breakout and More Instantly...
Collplant Holdings Company Name:
CQPTY Stock Symbol:
OTCMKTS Market:
Termination of Licensing Agreement for Bioprinting of Scaffolds for Lung Transplants PR Newswire REHOVOT, Israel , Feb. 25, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) a regenerative and aesthetics medicine company, today announced that on ...